A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Insulin detemir
Indications Type 1 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms EXPECT
Sponsors Novo Nordisk

03 Nov 2022 According to Novo Nordisk media release, the company has announced that Tresiba (insulin degludec injection) have improved glycemic control and can now be considered during pregnancy for use of pregnant women with diabetes. This update is based on the results from this study.
21 Dec 2020 Status changed from active, no longer recruiting to completed.
27 Aug 2020 This trial has been completed in Denmark, according to European Clinical Trials Database record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com